Back to News
Market Impact: 0.3
Ris-Rez Reduced Risk of Disease Progression or Death by 67% Versus Chemotherapy in Patients with Relapsed Osteosarcoma in China
Source: Nasdaq
Healthcare & Biotech
GSK announced positive results from ARTEMIS-011, a pivotal Phase III study in China evaluating risvutatug rezetecan (Ris-Rez) in patients with osteosarcoma. The excerpt provides no efficacy or safety figures, so the magnitude of the results and their potential market impact cannot be assessed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
GSK0.65
More News
- Hansoh and GSK drug extends survival in bone cancer study
- GSK cancer drug clears rectal tumours in 76% of patients in trial, data shows
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma